RedHill Biopharma
RedHill Biopharma Ltd. is an Israeli specialty biopharmaceutical company that develops and commercializes oral small molecule therapeutics for gastrointestinal, infectious, and oncological diseases, with one FDA-approved product (Talicia) and a mid-to-late-stage pipeline.
- Company typePublic
- Founded2009
- HeadquartersTel Aviv, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What RedHill Biopharma does
RedHill Biopharma Ltd. is an Israeli specialty biopharmaceutical company, founded in 2009 and listed on NASDAQ under ticker RDHL, that develops and commercializes proprietary oral small molecule therapeutics for gastrointestinal, infectious, and oncological diseases. Its sole commercial product is Talicia, an FDA-approved oral fixed-dose combination of omeprazole magnesium, amoxicillin, and rifabutin for the treatment of Helicobacter pylori infection in adults, listed as a first-line therapy in the 2024 American College of Gastroenterology Clinical Guideline and protected by composition patents through 2042.
The clinical pipeline is anchored by opaganib (ABC294640/Yeliva), a first-in-class investigational oral sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, and anti-cancer activity, administered to over 470 participants across studies and pursuing indications including prostate cancer (Phase 2 with Bayer/darolutamide), neuroblastoma, cholangiocarcinoma, triple-negative breast cancer, CLL, and Ebola virus disease under FDA Animal Rule development funded by BARDA. Additional pipeline assets include RHB-204 (next-generation oral fixed-dose antibiotic combination targeting MAP-positive Crohn's disease, with FDA Fast Track, Orphan, and QIDP designations), RHB-107/upamostat (a once-daily oral serine protease inhibitor for viral infections and oncology, including pancreatic cancer under Orphan Drug Designation), and RHB-102/Bekinda (extended-release ondansetron for gastroenteritis, gastritis, IBS-D, GLP-1-associated GI intolerance, and oncology-support CINV/RINV indications).
The business model combines Talicia product sales — co-commercialized in the U.S. with Cumberland Pharmaceuticals under a 50/50 net-revenue-share through Talicia Holdings Inc. (in which Cumberland holds a 30% equity stake) — with licensing/milestone revenue (up to $60 million from Hyloris for RHB-102 ex-North America), non-dilutive government funding (BARDA contract for opaganib Ebola development), and recurring equity financings (public offerings, registered direct offerings, convertible notes, and strategic private placements). The company maintains a dual operating footprint with headquarters in Tel Aviv, Israel and U.S. commercial operations in Raleigh, North Carolina.
RedHill Biopharma firmographics
Firmographics- Name
- RedHill Biopharma
- Legal name
- RedHill Biopharma Ltd.
- Website
- https://redhillbio.com
- Company type
- Public
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- RedHill Biopharma Ltd. is an Israeli specialty biopharmaceutical company that develops and commercializes oral small molecule therapeutics for gastrointestinal, infectious, and oncological diseases, with one FDA-approved product (Talicia) and a mid-to-late-stage pipeline.
- Ownership category
- akta.pro rank
RedHill Biopharma industry classification
Industry- Product category
- Specialty Pharmaceuticals (Gastroenterology/Infectious Diseases)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)
- akta.pro secondary industry
- Gastroenterology Specialty Pharmaceuticals (HLAIACAE)
Keywords
Where RedHill Biopharma is headquartered
LocationHeadquarters
- HQ city
- Tel Aviv
- HQ country
- Israel
- HQ region
- Middle East
Offices2 records
Markets served
RedHill Biopharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Talicia Product Sales: Revenue from U.S. sales of Talicia, an FDA-approved treatment for H. pylori infection, co-commercialized with Cumberland Pharmaceuticals with equal net revenue sharing.
- Licensing and Milestone Payments: Potential milestone payments and royalties from licensing agreements, including up to $60 million from Hyloris for RHB-102 commercialization outside North America.
- Government Funding: U.S. government funding through BARDA for development of opaganib as a medical countermeasure for Ebola virus disease under the FDA Animal Rule pathway.
- Strategic Investment: Investment proceeds from private placements and strategic investments, including $4 million from Cumberland Pharmaceuticals for 30% stake in Talicia Holdings Inc.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
RedHill Biopharma product offering
Product offeringCore offering
RedHill Biopharma is a specialty biopharmaceutical company that develops and commercializes proprietary oral small molecule drugs primarily targeting gastrointestinal and infectious diseases, with an expanding pipeline in oncology. The company markets Talicia, an FDA-approved oral fixed-dose combination therapy for H. pylori infection, in the U.S. and UAE, and develops a pipeline of investigational candidates including opaganib (SPHK2 inhibitor), RHB-204 (Crohn's disease antibiotic combination), RHB-107 (serine protease inhibitor), and RHB-102/Bekinda (ondansetron formulation).
Product overview
RedHill Biopharma is a specialty pharmaceutical company with a portfolio of proprietary oral small molecule drugs. The core commercial product is Talicia®, an FDA-approved treatment for H. pylori infection co-commercialized with Cumberland Pharmaceuticals. The R&D pipeline includes: opaganib (first-in-class SPHK2 inhibitor for oncology, viral, and metabolic diseases), RHB-204 (next-generation antibiotic for Crohn's disease), RHB-107 (serine protease inhibitor for viral infections and oncology), and RHB-102/Bekinda® (ondansetron formulation for GI disorders and oncology support). The company focuses on gastroenterology, infectious diseases, and oncology with mid-to-late-stage clinical development programs.
Differentiator
Problem solved
Functional benefit
Brands
- Talicia: FDA-approved treatment for Helicobacter pylori infection in adults. Oral capsule containing omeprazole magnesium, amoxicillin, and rifabutin. Co-commercialized in U.S. with Cumberland Pharmaceuticals.
Products and services
- Talicia FDA-approved prescription oral capsule combining omeprazole magnesium, amoxicillin, and rifabutin for the treatment of Helicobacter pylori infection in adults. Co-commercialized in the U.S. with Cumberland Pharmaceuticals and distributed through retail pharmacies in the U.S. and UAE.
- Opaganib (ABC294640, Yeliva) Proprietary first-in-class investigational oral sphingosine kinase-2 (SPHK2) selective inhibitor being developed for multiple oncology, viral, inflammatory, and metabolic indications including prostate cancer, neuroblastoma, cholangiocarcinoma, COVID-19, Ebola virus disease, triple-negative breast cancer, and CLL. Holds FDA Orphan Drug Designations for neuroblastoma and cholangiocarcinoma, and Rare Pediatric Disease Designation for neuroblastoma.
- RHB-204 Investigational next-generation fixed-dose oral antibiotic combination of clarithromycin, rifabutin, and clofazimine targeting Crohn's disease in MAP-positive patients. Optimized dosing profile from predecessor RHB-104 for enhanced tolerability, safety, and adherence.
- RHB-107 (Upamostat) First-in-class once-daily oral serine protease inhibitor being developed for viral infections (including COVID-19 and influenza), oncology (pancreatic cancer), and inflammatory gastrointestinal diseases. Host-directed antiviral targeting host cell factors involved in preparing spike protein for viral entry.
- RHB-102 (Bekinda) Proprietary bimodal immediate and extended-release once-daily oral ondansetron tablet (5-HT3 antagonist) targeting gastroenteritis, gastritis, IBS-D, GLP-1/GIP-associated GI intolerance, and oncology support indications including chemotherapy-induced and radiation-induced nausea and vomiting (CINV/RINV). Pursuing FDA approval through 505(b)(2) regulatory pathway.
Quantifiable outcome
- Opaganib demonstrated 70.2% mortality reduction in Phase 3 COVID-19 study
- +3 more outcomes
Companies that use RedHill Biopharma
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
RedHill Biopharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
RedHill Biopharma partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered minor and core.
- Penn State University / Apogee BiotechnologyminorResearch collaboration for preclinical studies demonstrating opaganib's effects in neuroblastoma models, showing enhancement of chemotherapy efficacy by destabilizing n-Myc oncogenic driver.
- University of KansasminorResearch collaboration showing pre-treatment with opaganib followed by low-dose diABZI potentiates STING-mediated effects and may augment anti-tumor immunity in triple-negative breast cancer.
- Cumberland Pharmaceuticals Inc.coreStrategic partnership including $4 million investment for 30% equity stake in newly formed Talicia Holdings Inc. and U.S. co-commercialization agreement for Talicia. Cumberland handles distribution and sales while sharing net revenues equally with RedHill. Partnership aims to enhance Talicia's market penetration and operational efficiency in the U.S.
- Hyloris Pharmaceuticals SAcoreExclusive worldwide development and commercialization licensing agreement, excluding North America, for RHB-102 (Bekinda). RedHill receives up to $60 million in potential milestone payments plus royalties. Hyloris advances development for oncology support (CINV/RINV) in the UK and other territories.
- Bayer AGcoreBayer provides financial support for Phase 2 study evaluating opaganib in combination with Bayer's darolutamide in men with metastatic castration-resistant prostate cancer (mCRPC). Study led by Professor Lisa Horvath from Chris O'Brien Lifehouse and ANZUP cancer trials group.
- Ramsay Hospital Research FoundationminorResearch foundation supporting the Phase 2 study of opaganib in combination with darolutamide for advanced prostate cancer.
- ANZUP (Australian and New Zealand Urogenital and Prostate Cancer Trials Group)minorClinical trials group leading the Phase 2 study of opaganib in advanced prostate cancer, registered with Australian New Zealand Clinical Trials Registry.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
RedHill Biopharma competitors and assessment
Company assessmentDirect peers
- Cumberland Pharmaceuticals: Cumberland is RedHill's direct U.S. co-commercialization partner for Talicia and holds a 30% equity stake in Talicia Holdings Inc. Both are small-cap U.S.-focused specialty pharmaceutical companies targeting gastroenterology and infectious disease, with similar sales models and pipeline-heavy business profiles.
- Phathom Pharmaceuticals: Phathom directly competes with RedHill in H. pylori infection with Voquezna (vonoprazan-based regimens), a newer branded alternative to Talicia. Both companies are U.S.-focused specialty pharma players concentrating on gastroenterology with first-line guideline-listed therapies.
- Hyloris Pharmaceuticals: Hyloris is RedHill's worldwide ex-North America licensing partner for RHB-102 (Bekinda) and operates a similar business model: a small specialty pharma that in-licenses, reformulates, and partners established molecules for niche indications. The two share a comparable pipeline-light, partnership-heavy commercialization approach.
- Eagle Pharmaceuticals: Eagle Pharmaceuticals is a small-cap specialty pharma with similar business model attributes (505(b)(2) reformulations, hospital/specialty channels) and is led by executives who previously held senior roles at RedHill, including former CBO Guy Goldberg. Direct overlap in specialty injectable and hospital-focused product strategies.
- ANI Pharmaceuticals: ANI is a comparable small-cap specialty pharma focused on niche generics and branded specialty products across therapeutic areas including GI and infectious disease. Both companies have similar scale, U.S. distribution models, and pipeline-driven growth strategies.
Broad incumbents
- Salix Pharmaceuticals: Salix is a long-established U.S. gastroenterology specialty pharma (now part of Bausch Health) and was where RedHill's President Rick Scruggs previously built his commercial career. Comparable focus on GI prescription brands distributed through U.S. specialty channels.
- Teva Pharmaceutical Industries: Teva is the largest Israeli pharmaceutical company and a historical employer of RedHill's CSO Mark Levitt, where he helped establish Teva's oncology franchise. Comparable in Israeli origin and specialty pharma orientation, though Teva operates at vastly greater scale as a global generics and specialty incumbent.
Emerging players
- Acurx Pharmaceuticals: Acurx is a similarly small clinical-stage antibiotic developer targeting resistant GI infections, with overlap in microbiome-targeted therapies and antibiotic-resistant bacterial indications. Comparable size, public-micro-cap status, and clinical-stage pipeline approach.
- BioXcel Therapeutics: BioXcel is a similarly small U.S. specialty biopharma developing immunology and oncology drugs with FDA designations (Orphan, Fast Track). Comparable pipeline-heavy profile, public-micro-cap market status, and reliance on FDA-designated indications for value creation.
- Innoviva: Innoviva is a specialty pharmaceutical holding company of similar small-cap scale that invests in late-stage development and commercial-stage assets through partnerships. Comparable in leveraging partnerships and licensing arrangements to capture value from clinical-stage programs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
RedHill Biopharma social profiles
Digital presenceRedHill Biopharma compliance and trust
Trust signalCompliance7 records
RedHill Biopharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
RedHill Biopharma leadership team
Management profileNumber of profiles
Profiles10 records
RedHill Biopharma subsidiaries and ownership
Company hierarchySubsidiaries2 records
RedHill Biopharma funding detail
Funding detailFunding overview
Funding rounds21 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RedHill Biopharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RedHill Biopharma
What does RedHill Biopharma do?
RedHill Biopharma is a specialty biopharmaceutical company that develops and commercializes proprietary oral small molecule drugs primarily targeting gastrointestinal and infectious diseases, with an expanding pipeline in oncology. The company markets Talicia, an FDA-approved oral fixed-dose combination therapy for H. pylori infection, in the U.S. and UAE, and develops a pipeline of investigational candidates including opaganib (SPHK2 inhibitor), RHB-204 (Crohn's disease antibiotic combination), RHB-107 (serine protease inhibitor), and RHB-102/Bekinda (ondansetron formulation).
Is RedHill Biopharma a public or private company?
RedHill Biopharma is a public company. It is classified as public and is currently operating.
When was RedHill Biopharma founded?
RedHill Biopharma was founded in 2009. It employs 11 to 50 people.
Where is RedHill Biopharma based?
RedHill Biopharma is headquartered in Tel Aviv, Israel, in the Middle East region.
How does RedHill Biopharma make money?
Four revenue lines are on record. Talicia Product Sales are the primary driver. The others are licensing and Milestone Payments, government Funding and strategic Investment.
Who are RedHill Biopharma's main competitors?
Direct peers on record are Cumberland Pharmaceuticals, Phathom Pharmaceuticals, Hyloris Pharmaceuticals, Eagle Pharmaceuticals and ANI Pharmaceuticals. Broad incumbents are Salix Pharmaceuticals and Teva Pharmaceutical Industries. Emerging players are Acurx Pharmaceuticals, BioXcel Therapeutics and Innoviva.
Does RedHill Biopharma have an API?
No public API is recorded for RedHill Biopharma.
What industry is RedHill Biopharma in?
RedHill Biopharma's product category is Specialty Pharmaceuticals (Gastroenterology/Infectious Diseases). Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals, with a secondary code of HLAIACAE, Gastroenterology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.